Prothena/$PRTA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Prothena
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Ticker
$PRTA
Sector
Primary listing
Employees
67
Headquarters
Dublin, Ireland
Website
Prothena Metrics
BasicAdvanced
$496M
-
-$4.53
-0.28
-
Price and volume
Market cap
$496M
Beta
-0.28
52-week high
$14.34
52-week low
$4.32
Average daily volume
490K
Financial strength
Current ratio
7.717
Quick ratio
7.53
Long term debt to equity
1.956
Total debt to equity
2.985
Profitability
EBITDA (TTM)
-183.657
Gross margin (TTM)
-1,292.52%
Net profit margin (TTM)
-2,520.57%
Operating margin (TTM)
-1,905.82%
Effective tax rate (TTM)
-21.54%
Revenue per employee (TTM)
$140,000
Management effectiveness
Return on assets (TTM)
-26.40%
Return on equity (TTM)
-63.62%
Valuation
Price to revenue (TTM)
51.194
Price to book
1.77
Price to tangible book (TTM)
1.77
Price to free cash flow (TTM)
-3.028
Free cash flow yield (TTM)
-33.02%
Free cash flow per share (TTM)
-3.041
Growth
Revenue change (TTM)
-92.83%
Earnings per share change (TTM)
99.36%
3-year revenue growth (CAGR)
-43.57%
10-year revenue growth (CAGR)
19.68%
3-year earnings per share growth (CAGR)
22.46%
10-year earnings per share growth (CAGR)
5.49%
What the Analysts think about Prothena
Analyst ratings (Buy, Hold, Sell) for Prothena stock.
Prothena Financial Performance
Revenues and expenses
Prothena Earnings Performance
Company profitability
Prothena News
AllArticlesVideos
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
Business Wire·5 days ago
Prothena Announces up to $100 Million Share Repurchase Plan
Business Wire·2 weeks ago
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Prothena stock?
Prothena (PRTA) has a market cap of $496M as of March 14, 2026.
What is the P/E ratio for Prothena stock?
The price to earnings (P/E) ratio for Prothena (PRTA) stock is 0 as of March 14, 2026.
Does Prothena stock pay dividends?
No, Prothena (PRTA) stock does not pay dividends to its shareholders as of March 14, 2026.
When is the next Prothena dividend payment date?
Prothena (PRTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Prothena?
Prothena (PRTA) has a beta rating of -0.28. This means that it has an inverse relation to market volatility.